Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4767-4773

  Zeuner, Ann ^a,b   Signore, Michele ^a   Martinetti, Daniela ^a   Bartucci, Monica ^a   Peschle, Cesare ^a   De Maria, Ruggero ^a,b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Istituto Oncologico del Mediterraneo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; PROTEIN KINASE B; STEM CELL FACTOR;

APOPTOSIS; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; CYTARABINE; ENZYME ACTIVATION; ERYTHROID PROGENITOR CELLS; HUMANS; MEGAKARYOCYTES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; STEM CELL FACTOR; THROMBOCYTOPENIA; VINCRISTINE;

EID: 34250373620     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4303     Document Type: Article

References (33)

1. Kaushansky K. The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Hematol Oncol Clin North Am 1996;10:431-55.
2. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001;19:1137-46.
3. De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002;100:1310-7.
4. De Maria R, Zeuner A Eramo A. et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1, Nature 1999;401:489-93.
5. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004;10:64-71.
6. + cells. Blood 1993;82:84-95.
7. + cells. Blood 1998;91:830-43.
8. Guerriero R, Mattia G, Testa U, et al. Stromal cell-derived factor la increases polyploidization of megakaryocytes generated by human hematopoietic progenitor cells. Blood 2001;97:2587-95.
9. Antonchuk J, Hyland CD, Hilton DJ, Alexander WS. Synergistic effects on erythropoiesis, thrombopoiesis, and stem cell competitiveness in mice deficient in thrombopoietin and steel factor receptors. Blood 2004;104:1306-13.
10. Zeuner A, Pedini F, Signore M, et al. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood 2006;107:3495-502.
11. Guerriero R, Testa U Gabbianelli M, et al. Unilineage megakaryocytic proliferation and differentiation of purified hematopoietic progenitors in serum-free liquid culture. Blood 1995;86:3725-36.
12. Bonci D, Cittadini A, Latronico MV, et al. "Advanced" generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther 2003;10:630-6.
13. Zeuner A, Pedini F, Signore M, et al. Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood 2003;102:87-93.
14. Schubert KM, Duronio V. Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis. Biochem J 2001;356:473-80.
15. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-14.
16. Maslak P, Nimer SD. The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia. Semin Hematol 1998;35:253-60.
17. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-69.
18. Demetri GD. Pharmacologic treatment options in patients with thrombocytopenia. Semin Hematol 2000; 37:11-8.
19. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001;61:4301-5.
20. Blaise D, Faucher C, Vey N, et al. Rescue of haemopoiesis by a combination of growth factors including stem-cell factor. Lancet 2000;356:1325-6.
21. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
22. van Deventer HW, Hall MD, Orlowski RZ, et al. Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. Am J Hematol 2002;71:184-90.
23. Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 2003;102:4298-305.
24. Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991;78:2962-8.
25. Bellone G, Carbone A, Sibona N, et al. Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 2001;61:2200-6.
26. Broudy VC, Smith FO, Lin N, et al. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood 1992;80:60-7.
27. Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 2005;11:993-9.
28. Arcasoy MO, Amin K, Karayal AE, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-8.
29. Arcasoy MO, Amin K, Chou SC, et al. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005;11:20-7.
30. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004;100:2376-86.
31. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477-87.
32. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-22.
33. Singer CF, Hudelist G, Lamm W, et al. Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 2004;11:861-9.